EARLY EXPERIENCE WITH PATIENT TREATMENT AND DRUG DELIVERY WITH IRRA*flow*

An Automatically Irrigating and Draining Ventricular Catheter

Presented by Babar Khan, MD

and from Nicholas Brandmeir, MD, and WVU Rockefeller Neuroscience Institute at The Neurosurgical Society of the Virginias Annual Meeting

The need for improving EVDs

EVD COMPLICATION RATES

- Infection: 4-20%
 - Increases with occlusion
 - Current abx impregnated catheters only prevent gram + infection
- Revision: 13%
 - Occlusion: 25-50% in IVH
- Hemorrhage: 8%

Conclusion

Preliminary data confirms that IRRA*flow* might reduce rates of catheter occlusion, infections, symptomatic and radiographic vasospasm.

Future prospective (randomized) studies will be conducted to confirm these findings.

Yuen J, Selbi W, Muquit S, Berei T. Complication rates of external ventricular drain insertion by surgeons of different experience. Ann R Coll Surg Engl [Internet] 2018;100:221–5

Atkinson RA, Fikrey L, Vail A, Patel HC. Silver-impregnated external-ventricular-drain-related cerebrospinal fluid infections: a meta-analysis. J Hosp Infect [Internet] 2016;92:263–72

Talibi SS, Silva AH, Afshari FT, Hodson J, Roberts SA, Oppenheim B, et al. The implementation of an external ventricular drain care bundle to reduce infection rates. Br J Neurosurg [Internet] 2020;34:181–6.

Gilard V, Djoubairou BO, Lepetit A, Metayer T, Gakuba C, Gourio C, et al. Small versus Large Catheters for Ventriculostomy in the Management of Intraventricular Hemorrhage. World Neurosurg [Internet] 2017;97:117–22.



Applications

• IVH

- Irrigation
- tPA infusion

VENTRICULITIS

- IT infusion of abx
- SAH
 - IT infusion of antivasospasm agents (nicardipine)
- SDH
 - Irrigation



Patient Characteristics

45 patients

Gender Male 28 (62%) Female 17 (38%) Length of Stay (days) ICU 7.4 ± 5.8 Hospital 14.4 ± 9.8 Age (years) 60.2 ± 17.3 Indications IVH 23 (51.1%) SAH HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2) 12 (26.6%) HH4 (2), HH5 (2) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Ensertion Location R frontal 26 (57.7%) Insertion Location R frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole 13 (28.8%)			
Female 17 (38%) Length of Stay (days) ICU 7.4 ± 5.8 Hospital 14.4 ± 9.8 Age (years) 60.2 ± 17.3 Indications IVH 23 (51.1%) SAH HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2) 12 (26.6%) HH4 (2), HH5 (2) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Ventriculitis 3 (6.6%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Insertion Method Stealth (bedside) 18 (40%)	Gender	Male	28 (62%)
Length of Stay (days) ICU 7.4 ± 5.8 Hospital 14.4 ± 9.8 Age (years) 60.2 ± 17.3 Indications IVH 23 (51.1%) SAH HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2) 12 (26.6%) HH4 (2), HH5 (2) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Ventriculitis 3 (6.6%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Xerage Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%)		Female	17 (38%)
Length of Stay (days) ICU 7.4 ± 5.8 Hospital 14.4 ± 9.8 Age (years) 60.2 ± 17.3 Indications IVH 23 (51.1%) SAH HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2) 12 (26.6%) 12 (26.6%) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Ventriculitis 3 (6.6%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%)			
Hospital 14.4 ± 9.8 Age (years) 60.2 ± 17.3 Indications IVH $23 (51.1\%)$ SAH 12 (26.6%) HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2) 13 (28.8%) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/hurrhole 13 (28.8%)	Length of Stay (days)	ICU	7.4 ± 5.8
Age (years) 60.2 ± 17.3 Indications IVH $23 (51.1\%)$ SAH SAH 12 (26.6%) HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2) 12 (26.6%) SDH 13 (28.8%) Ventriculitis Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole		Hospital	14.4 ± 9.8
Indications IVH 23 (51.1%) SAH HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2) 12 (26.6%) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Ventriculitis 3 (6.6%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/hurrhole 13 (28.8%)		Age (years)	60.2 ± 17.3
Indications IVH 23 (51.1%) SAH HH1 (0), HH2 (2), HH3 (6), H12 (26.6%) 12 (26.6%) HH4 (2), HH5 (2) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole 13 (28.8%)			
SAH HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2) 12 (26.6%) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole	Indications	IVH	23 (51.1%)
HH I (0), HH2 (2), HH3 (0), HH4 (2), HH5 (2) 12 (26.6%) SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole		SAH	10 (00 00/)
SDH 13 (28.8%) Ventriculitis 3 (6.6%) Hydrocephalus (Other) 2 (4.4%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/hurrhole		HH1 (0), HH2 (2), HH3 (6), HH4 (2), HH5 (2)	12 (20.0%)
Ventriculitis3 (6.6%)Hydrocephalus (Other)2 (4.4%)Insertion LocationR frontal26 (57.7%)L frontal6 (13.3%)Burr hole5 (11.1%)Craniotomy8 (17.7%)Average Duration(days)6.8 ± 4.9Insertion MethodStealth (bedside)18 (40%)Anatomic14 (31.1%)Craniotomy/burrhole13 (28.8%)		SDH	13 (28.8%)
Hydrocephalus (Other) 2 (4.4%) Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/hurrhole		Ventriculitis	3 (6.6%)
Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole 13 (28.8%)		Hydrocephalus (Other)	2 (4.4%)
Insertion Location R frontal 26 (57.7%) L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%)			
L frontal 6 (13.3%) Burr hole 5 (11.1%) Craniotomy 8 (17.7%) Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole 13 (28.8%)	Insertion Location	R frontal	26 (57.7%)
Burr hole5 (11.1%)Craniotomy8 (17.7%)Average Duration(days)6.8 ± 4.9Insertion MethodStealth (bedside)18 (40%)Anatomic14 (31.1%)Craniotomy/burrhole13 (28.8%)		L frontal	6 (13.3%)
Craniotomy8 (17.7%)Average Duration(days)6.8 ± 4.9Insertion MethodStealth (bedside)18 (40%)Anatomic14 (31.1%)Craniotomy/burrhole13 (28.8%)		Burr hole	5 (11.1%)
Average Duration(days) 6.8 ± 4.9 Insertion MethodStealth (bedside)18 (40%)Anatomic14 (31.1%)Craniotomy/burrhole13 (28.8%)		Craniotomy	8 (17.7%)
Average Duration (days) 6.8 ± 4.9 Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole 13 (28.8%)			
Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%) Craniotomy/burrhole 13 (28.8%)	Average Duration	(days)	6.8 ± 4.9
Insertion Method Stealth (bedside) 18 (40%) Anatomic 14 (31.1%)			
Anatomic 14 (31.1%)	Insertion Method	Stealth (bedside)	18 (40%)
Craniotomy/burrhole 13 (28 8%)		Anatomic	14 (31.1%)
		Craniotomy/burrhole	13 (28.8%)

Outcomes

Complications	Ventriculitis	1 (2.2%)
	Mortality	9 (20%)
Intrathecal Medications administered	tPA	9 (20%)
	Vancomycin	2 (4.4%)
Catheter Occlusion		0%
Shunt dependence (IVH)		3/23 (13%)**
Vasospasm	Clinical	2/12 (17%)***
	Radiographic	3/12 (25%)***
SDH	MLS before: 4.9±2.6	Percentage improved
	MLS after 2d: 0.8± 1.2	13/13 (100%)

CT and endoscopic images confirm impact of IRRA*flow*'s automated irrigation



- IRRA*flow* inserted directly in clot
- Irrigation performed with tPA
- Endoscopic evaluation performed on day 4



NO OCCLUSION FORMATION EVEN IN HEAVY CLOT BURDEN

Irrigation from IRRA*flow* cleansing the catheter tip, keeping the **catheter free** of occlusions

Images provided by Dr. Nicholas Brandmeir

* Compared to 19% permanent, 41% temporary occlusion. Fargen ett al. JNS 2016

- ** Compared to 18% in literature. Clear III trial. Murthy et al. Neurology 2017
- *** Compared to 40-70% in literature. Bracard et al. Interventional Neuroradiology 2008

